These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21358665)

  • 1. Randomized studies of PSA screening: an opinion.
    Sartor O
    Asian J Androl; 2011 May; 13(3):364-5. PubMed ID: 21358665
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.
    Lin K; Lipsitz R; Miller T; Janakiraman S;
    Ann Intern Med; 2008 Aug; 149(3):192-9. PubMed ID: 18678846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial. PSA screening and low risk prostate cancer, what's going on? are we shooting the messenger?
    Martínez-Salamanca JI
    Arch Esp Urol; 2012 Mar; 65(2):209-14. PubMed ID: 22414449
    [No Abstract]   [Full Text] [Related]  

  • 4. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making.
    Venderbos LD; Roobol MJ
    Asian J Androl; 2011 Mar; 13(2):219-24. PubMed ID: 21297655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The controversy over PSA testing: has anything changed?
    Johns Hopkins Med Lett Health After 50; 2009 Aug; 21(6):1-2. PubMed ID: 19722309
    [No Abstract]   [Full Text] [Related]  

  • 6. PSA screening said to reduce prostate-cancer deaths, or does it?
    McCarthy M
    Lancet; 1998 May; 351(9115):1563. PubMed ID: 10326552
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for prostate cancer.
    Ruffin MT
    J Fam Pract; 1999 Aug; 48(8):581-2. PubMed ID: 10496634
    [No Abstract]   [Full Text] [Related]  

  • 8. PSA screening: correlating noise with noise?
    McGregor M
    CMAJ; 2002 Aug; 167(4):340; author reply 340. PubMed ID: 12197684
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Walsh PC
    J Natl Cancer Inst; 2014 Feb; 106(2):djt432. PubMed ID: 24399847
    [No Abstract]   [Full Text] [Related]  

  • 10. RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Carlsson S; Roobol MJ; Schröder FH; Hugosson J; Auvinen A
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24771874
    [No Abstract]   [Full Text] [Related]  

  • 11. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of PSA screening on mortality. PLCO project team (prostate, lung, colorectal, ovarian cancer screening trial)].
    Heidenreich A; Nitschmann S
    Internist (Berl); 2010 Feb; 51(2):219-20. PubMed ID: 20107755
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer screening: biases and the need for consensus.
    Brawley OW
    J Natl Cancer Inst; 2013 Oct; 105(20):1522-4. PubMed ID: 24092919
    [No Abstract]   [Full Text] [Related]  

  • 14. PSA testing.
    Frydenberg M
    Aust Fam Physician; 2003 Jun; 32(6):396. PubMed ID: 12833760
    [No Abstract]   [Full Text] [Related]  

  • 15. Response.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2014 Feb; 106(2):djt433. PubMed ID: 24399848
    [No Abstract]   [Full Text] [Related]  

  • 16. Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis.
    Carter HB
    Eur Urol; 2014 Dec; 66(6):973-4. PubMed ID: 25018035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Surveillance for Localized Prostate Cancer: No Increased Mortality, but Higher Rates of Clinical Progression.
    Ebell MH
    Am Fam Physician; 2017 Feb; 95(3):196. PubMed ID: 28145675
    [No Abstract]   [Full Text] [Related]  

  • 19. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.
    de Vries SH; Raaijmakers R; Kranse R; Blijenberg BG; Schröder FH
    J Urol; 2004 Dec; 172(6 Pt 1):2193-6. PubMed ID: 15538230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.